Patients who have hormone-receptor-positive tumors receive endocrine therapy, and those with ERBB2-positive cancer receive a monotherapy of an ERBB2-targeted antibody or in combination with chemotherapy [21]. This evidence concerns the gene ERBB2 and cancer.